F
Finbarr O'Harte
Researcher at Ulster University
Publications - 176
Citations - 5871
Finbarr O'Harte is an academic researcher from Ulster University. The author has contributed to research in topics: Insulin & Diabetes mellitus. The author has an hindex of 44, co-authored 172 publications receiving 5414 citations. Previous affiliations of Finbarr O'Harte include Royal College of Surgeons in Ireland & Creighton University.
Papers
More filters
Journal ArticleDOI
Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion
Neville H. McClenaghan,Christopher R. Barnett,Eric Ah-Sing,Yasser Abdel-Wahab,Finbarr O'Harte,Tai-Wook Yoon,Sara K. Swanston-Flatt,Peter R. Flatt +7 more
TL;DR: High-performance liquid chromatography analysis demonstrated that insulin was the major product secreted under stimulatory conditions, and western blotting confirmed that BRIN-BD11 cells expressed the GLUT2 glucose transporter, confirming an intact glucose sensing mechanism.
Journal ArticleDOI
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
John R. Lindsay,Nicola A. Duffy,Aine McKillop,Joy Ardill,Finbarr O'Harte,Peter R. Flatt,Patrick M. Bell +6 more
TL;DR: This work investigated the acute effects of metformin on DPP IV activity in Type 2 diabetes to elucidate inhibition of DPPIV as a possible mechanism of action.
Journal ArticleDOI
Chemical Ablation of Gastric Inhibitory Polypeptide Receptor Action by Daily (Pro3)GIP Administration Improves Glucose Tolerance and Ameliorates Insulin Resistance and Abnormalities of Islet Structure in Obesity-Related Diabetes
Victor A. Gault,Nigel Irwin,Brian D. Green,Jane T. McCluskey,Brett Greer,Clifford J. Bailey,Patrick Harriott,Finbarr O'Harte,Peter R. Flatt +8 more
TL;DR: A role for GIP in obesity-related glucose intolerance is highlighted and the potential of specific GIP-R antagonists as a new class of drugs for the alleviation of insulin resistance and treatment of type 2 diabetes is emphasized.
Journal ArticleDOI
Effects of the novel (Pro 3 )GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob /ob) mice: evidence that GIP is the major physiological incretin
TL;DR: Feed studies in one commonly used animal model of obesity and diabetes, (ob/ob) mice, suggest that GIP is the major physiological component of the enteroinsular axis, contributing approximately 80% to incretin-induced insulin release.
Journal ArticleDOI
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.
TL;DR: The antidiabetic properties of the best GLP-1 and GIP analogues indeed promise to provide the basis for novel, effective and long-acting drugs for type 2 diabetes therapy and are currently being pursued actively by the pharmaceutical industry.